Only 7% Indians Want Doctors To Prescribe Only Generic Drugs: Survey

Mumbai : Just seven per cent of Indians support guidelines by the National Medicine Commission (NMC) asking doctors to prescribe only generic medicines, according to an online survey.
As many as 85 per cent Indians supported guidelines that prohibit doctors from receiving gifts and commissions from various establishments, said LocalCircles, a social media platform for community-building.
Around 60 per cent people preferred doctors to mention the names of both the branded drug and the generic version. People said the choice would enable them to make decisions about medication by availability and affordability.
As many as 72 per cent of respondents believed that their doctors are receiving commissions from multiple sources, including labs, nursing homes, hospitals, pharmaceutical companies, and chemists.
The NMC issued a directive on August 2, mandating doctors to prescribe generic salts or drugs instead of branded generics. Failure to comply could lead to penalties, including the suspension of medical licences upon repeated violations.
The survey collected responses from more than 43,000 citizens in 326 districts. Respondents emphasised the importance of swift investigations and actions against violators, accompanied by transparent communication with complainants to instill faith in the process.
LocalCircles plans to present the survey findings to stakeholders involved in implementing the NMC guidelines.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March